EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Andros Pharmaceuticals Co's Enterprise Value is NT$522.49 Mil.
Andros Pharmaceuticals Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-47.22 Mil. Therefore, Andros Pharmaceuticals Co's EV-to-FCF for today is -11.06.
The historical rank and industry rank for Andros Pharmaceuticals Co's EV-to-FCF or its related term are showing as below:
ROCO:6917'
s EV-to-FCF Range Over the Past 10 Years
Min: -29.25 Med: -18.95 Max: -6.65
Current: -11.06
During the past 5 years, the highest EV-to-FCF of Andros Pharmaceuticals Co was -6.65. The lowest was -29.25. And the median was -18.95.
ROCO:6917's EV-to-FCF is ranked worse than 100% of 378
companies
in the Biotechnology industry
Industry Median: 8.345
vs ROCO:6917: -11.06
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Andros Pharmaceuticals Co's EV-to-FCF
For the Biotechnology subindustry, Andros Pharmaceuticals Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Andros Pharmaceuticals Co's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Andros Pharmaceuticals Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Andros Pharmaceuticals Co's EV-to-FCF falls into.
Andros Pharmaceuticals Co's current Enterprise Value is NT$522.49 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Andros Pharmaceuticals Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-47.22 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Andros Pharmaceuticals Co (ROCO:6917) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Andros Pharmaceuticals Co's PE Ratio for today is calculated as:
Andros Pharmaceuticals Co's share price for today is NT$20.95.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Andros Pharmaceuticals Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-1.870.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Andros Pharmaceuticals Co EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Andros Pharmaceuticals Co's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Andros Pharmaceuticals Co (ROCO:6917) Business Description
Andros Pharmaceuticals Co Ltd is a biopharmaceutical company engaged in developing novel drug delivery platform technologies. The firm focuses on the development of topical new dosage forms and non-viral gene delivery systems, with the current pipeline indicated for pain management, DNA repair, and gene therapy. Its product line comprises New Dosage Forms (Topical), Super Generics (Topical), High-End Cosmetic Ingredients (Topical), and Gene Delivery Systems (Injectable).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ROCO:6917 has been successfully added to your